



Supplementary Fig. 3. Reproducibility of IMmunoTherapy Against Gastric Cancer (IMAGiC) model using a quantitative real-time polymerase chain reaction platform. (A) Correlations between IMAGiC model, Response Evaluation Criteria in Solid Tumors (RECIST) group ($r^2=0.83$), Epstein-Barr virus (EBV; $r^2=0.49$), and microsatellite unstable (MSI; $r^2=0.66$). (B, C, D) Boxplot comparing IMAGiC scores between RECIST groups ($P=0.0051$), MSI subtypes ($P=0.0028$), and EBV subtypes ($P=0.081$). PD-L1, programmed death ligand 1; CPS, combined positive score; TMB, tumor mutational burden; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.